Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 765  
ORIGINAL ARTICLE
Year : 2016  |  Volume : 15  |  Issue : 3  |  Page : 173-178

Gastrointestinal side effects of the radioiodine therapy for the patients with differentiated thyroid carcinoma two days after prescription


1 Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences; Department of Nuclear Medicine, Research Institute for Nuclear Medicine, Shariati Hospital, Tehran, Iran
3 Department of Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Statistical in Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Radiation Sciences, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
6 Department of Nuclear Medicine, Research Institute for Nuclear Medicine, Shariati Hospital, Tehran, Iran

Correspondence Address:
Sina Izadyar
Department of Nuclear Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran
Iran
Login to access the Email id


DOI: 10.4103/1450-1147.174703

PMID: 27651737

Rights and Permissions

Iodine-131 (I-131) therapy is one of the conventional approaches in the treatment of patients with differentiated thyroid carcinoma (DTC). The radioiodine agents also accumulate in the other organs that cause pain and damage to the patients. Radioiodine therapy is associated with various gastrointestinal (GI) toxicities. In this study, GI side effects of the radioiodine therapy were investigated. GI toxicities of the radioiodine therapy were studied in 137 patients with histologically proven DTC in Jun-Nov 2014. All the patients were treated by radioiodine agents in the research institute of Shariati Hospital, Tehran, Iran. The patients were examined 48 h after prescription (before discharge) and their GI side effects were registered. Correlation of the age, gender, administered dose, administered dose per body weight as the independent factors, and GI side effects were analyzed using the Pearson correlation test with Statistical Package for the Social Sciences (SPSS) version 20. Regression coefficients and linearity of the variable were investigated by MATLAB software. Line fitting was performed using MATLAB curve-fitting toolbox. From the subjects, 38 patients had GI complaints (30.4%). Significant factors influencing GI side effects were dose per body weight and administered doses. There was no significant correlation between age and gender as the independent parameters and GI complaints. The most prevalent GI side effect was nausea that occurs in 26.4% of the patients. From the results, it could be concluded that the GI side effects could be prevented by administering a safe radioiodine dose value less than 5,550 MBq.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2545    
    Printed55    
    Emailed0    
    PDF Downloaded293    
    Comments [Add]    
    Cited by others 3    

Recommend this journal